**9. References**

"www.opsona.com."

Abdollahi-Roodsaz, S., L. A. Joosten, et al. (2008). "Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production." *Arthritis Rheum* 58(12): 3753-3764.

Targeting DAMP Activation of

320.

*Rheum Dis* 67(4): 547-554.

Toll-Like Receptors: Novel Pathways to Treat Rheumatoid Arthritis? 227

Drexler, S. K., P. Kong, et al. (2010). "SIGIRR/TIR-8 is an inhibitor of Toll-like receptor

Fleischmann, R. M., J. Tesser, et al. (2006). "Safety of extended treatment with anakinra in patients with rheumatoid arthritis." *Ann Rheum Dis* 65(8): 1006-1012. Foell, D., H. Wittkowski, et al. (2007). "Mechanisms of disease: a 'DAMP' view of

Frasnelli, M. E., D. Tarussio, et al. (2005). "TLR2 modulates inflammation in zymosan-

Genovese, M. C. (2009). "Inhibition of p38: has the fat lady sung?" *Arthritis Rheum* 60(2): 317-

Genovese, M. C., M. Schiff, et al. (2008). "Efficacy and safety of the selective co-stimulation

Gondokaryono, S. P., H. Ushio, et al. (2007). "The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4." *J Leukoc Biol* 82(3): 657-665. Guo, H., N. T. Ingolia, et al. (2010). "Mammalian microRNAs predominantly act to decrease

Hasan, U., C. Chaffois, et al. (2005). "Human TLR10 is a functional receptor, expressed by B

Heil, F., H. Hemmi, et al. (2004). "Species-specific recognition of single-stranded RNA via

Ho, P. P., L. Y. Lee, et al. (2010). "Autoimmunity against fibrinogen mediates inflammatory

Hodgkinson, C.P. and Patel. K. et al. (2008). "Functional Toll-like receptor 4 mutations modulate the response to fibrinogen." *Thromb Haemost.* 100(2): 301-307. Huang, Q., Y. Ma, et al. (2007). "Increased macrophage activation mediated through toll-like

Ivashkiv, L. B. (2008). "A signal-switch hypothesis for cross-regulation of cytokine and TLR

Iwahashi, M., M. Yamamura, et al. (2004). "Expression of Toll-like receptor 2 on CD16+

James, E. A., A. K. Moustakas, et al. (2010). "HLA-DR1001 presents "altered-self" peptides

Jin, M. S., S. E. Kim, et al. (2007). "Crystal structure of the TLR1-TLR2 heterodimer induced

Johnson, G. B., G. J. Brunn, et al. (2004). "Cutting edge: an endogenous pathway to systemic

Jones, G. and C. Ding (2010). "Tocilizumab: a review of its safety and efficacy in rheumatoid

by binding of a tri-acylated lipopeptide." *Cell* 130(6): 1071-1082.

arthritis." *Clin Med Insights Arthritis Musculoskelet Disord* 3: 81-89.

blood monocytes and synovial tissue macrophages in rheumatoid arthritis."

derived from joint-associated proteins by accepting citrulline in three of its binding

inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor

receptors in rheumatoid arthritis." *Arthritis Rheum* 56(7): 2192-2201.

modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy." *Ann* 

cells and plasmacytoid dendritic cells, which activates gene transcription through

rheumatoid arthritis." *Arthritis Rheum* 62(8): 2249-2261.

inflammatory arthritis." *Nat Clin Pract Rheumatol* 3(7): 382-390.

induced arthritis in mice." *Arthritis Res Ther* 7(2): R370-379.

target mRNA levels." *Nature* 466(7308): 835-840.

toll-like receptor 7 and 8." *Science* 303(5663): 1526-1529.

signalling pathways." *Nat Rev Immunol* 8(10): 816-822.

MyD88." *J Immunol* 174(5): 2942-2950.

*Arthritis Rheum* 50(5): 1457-1467.

4." *J Immunol* 172(1): 20-24.

pockets." *Arthritis Rheum* 62(10): 2909-2918.

arthritis in mice." *J Immunol* 184(1): 379-390.

signaling in primary human cells and regulates inflammation in models of


Abdollahi-Roodsaz, S., L. A. Joosten, et al. (2008). "Stimulation of TLR2 and TLR4

Abdollahi-Roodsaz, S., L. A. Joosten, et al. (2007). "Inhibition of Toll-like receptor 4 breaks

Abeyama, K., D. M. Stern, et al. (2005). "The N-terminal domain of thrombomodulin

Andersson, U. and H. Erlandsson-Harris (2004). "HMGB1 is a potent trigger of arthritis." *J* 

Babelova, A., K. Moreth, et al. (2009). "Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors." *J Biol Chem* 284(36): 24035-24048. Barrat, F. J., T. Meeker, et al. (2005). "Nucleic acids of mammalian origin can act as

Barrera, V., O. A. Skorokhod, et al. (2011). "Host fibrinogen stably bound to hemozoin

Bax, M., J. van Heemst, et al. (2011). "Genetics of rheumatoid arthritis: what have we

Bleharski, J. R., V. Kiessler, et al. (2003). "A role for triggering receptor expressed on myeloid

Brentano, F., O. Schorr, et al. (2005). "RNA released from necrotic synovial fluid cells

Brunn, G. J., M. K. Bungum, et al. (2005). "Conditional signaling by Toll-like receptor 4."

Buch, M. H., J. S. Smolen, et al. (2011). "Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis." *Ann Rheum Dis* 70(6): 909-920. Chen, G., J. Li, et al. (2005). "Suppression of HMGB1 release by stearoyl

Chen, T., M. Rimpilainen, et al. (2003). "Bacterial components in the synovial tissue of

Choe, J. Y., B. Crain, et al. (2003). "Interleukin 1 receptor dependence of serum transferred

Di Paolo, J. A., T. Huang, et al. (2011). "Specific Btk inhibition suppresses B cell- and myeloid

Dong, L., S. Ito, et al. (2004). "Suppressive oligonucleotides protect against collagen-induced

*Invest* 118(1): 205-216.

*J Clin Invest* 115(5): 1267-1274.

erythematosus." *J Exp Med* 202(8): 1131-1139.

of hemozoin action." *Blood* 117(21): 5674-5682.

immune response." *J Immunol* 170(7): 3812-3818.

experimental sepsis." *J Lipid Res* 46(4): 623-627.

cell-mediated arthritis." *Nat Chem Biol* 7(1): 41-50.

arthritis in mice." *Arthritis Rheum* 50(5): 1686-1689.

*Intern Med* 255(3): 344-350.

learned?" *Immunogenetics*.

*Rheum* 52(9): 2656-2665.

*FASEB J* 19(7): 872-874.

*Arthritis Rheum* 49(3): 328-334.

537-542.

2957-2967.

differentially skews the balance of T cells in a mouse model of arthritis." *J Clin* 

the inflammatory loop in autoimmune destructive arthritis." *Arthritis Rheum* 56(9):

sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism."

endogenous ligands for Toll-like receptors and may promote systemic lupus

rapidly activates monocytes via TLR-4 and CD11b/CD18-integrin: a new paradigm

cells-1 in host defense during the early-induced and adaptive phases of the

activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3." *Arthritis* 

lysophosphatidylcholine:an additional mechanism for its therapeutic effects in

patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction."

arthritis can be circumvented by toll-like receptor 4 signaling." *J Exp Med* 197(4):


Targeting DAMP Activation of

1447-1450.

1001.

3856-3865.

4507-4519.

*Arthritis Res Ther* 12(3): R103.

cultures." *Arthritis Res Ther* 13(1): R33.

signalling." *Mediators Inflamm* 2010.

signalling." *Nat Rev Immunol* 11(3): 163-175.

by the TLR4-MD-2 complex." *Nature* 458(7242): 1191-1195.

Proliferation." *J Pharmacol Exp Ther* 312(1): 373-381.

arthritis." *Arthritis Rheum* 58(12): 3765-3775.

(CD16) pathways." *PLoS Pathog* 5(6): e1000464.

*Nat Med* 15(7): 774-780.

Toll-Like Receptors: Novel Pathways to Treat Rheumatoid Arthritis? 229

Meng, L., W. Zhu, et al. (2010). "Toll-like receptor 3 upregulation in macrophages

Midwood, K., S. Sacre, et al. (2009). "Tenascin-C is an endogenous activator of Toll-like

Musumeci, D., G. N. Roviello, et al. (2007). "Bent oligonucleotide duplexes as HMGB1

Nic An Ultaigh, S., T. P. Saber, et al. (2011). "Blockade of Toll-like receptor 2 prevents

O'Neill, L. A., F. J. Sheedy, et al. (2011). "MicroRNAs: the fine-tuners of Toll-like receptor

Ospelt, C., F. Brentano, et al. (2008). "Overexpression of toll-like receptors 3 and 4 in

Piccinini, A. M. and K. S. Midwood (2010). "DAMPening inflammation by modulating TLR

Podolin, P. L., J. F. Callahan, et al. (2005). "Attenuation of murine collagen-induced arthritis

Pullerits, R., I. M. Jonsson, et al. (2003). "High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis." *Arthritis Rheum* 48(6): 1693-1700. Radstake, T. R., B. Franke, et al. (2004). "The Toll-like receptor 4 Asp299Gly functional

Radstake, T. R., M. F. Roelofs, et al. (2004). "Expression of toll-like receptors 2 and 4 in

Ranjith-Kumar, C. T., K. E. Duffy, et al. (2008). "Single-stranded oligonucleotides can inhibit

Rice, J. W., J. M. Veal, et al. (2008). "Small molecule inhibitors of Hsp90 potently affect

Rittirsch, D., M. A. Flierl, et al. (2009). "Cross-talk between TLR4 and FcgammaReceptorIII

by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell

variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome." *Arthritis Rheum* 50(3): 999-

rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma." *Arthritis Rheum* 50(12):

cytokine production induced by human toll-like receptor 3." *Mol Cell Biol* 28(14):

inflammatory disease pathways and exhibit activity in models of rheumatoid

participates in the initiation and maintenance of pristane-induced arthritis in rats."

receptor 4 that is essential for maintaining inflammation in arthritic joint disease."

inhibitors: a comparative study." *Nucleosides Nucleotides Nucleic Acids* 26(10-12):

spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant

synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis." *Arthritis Rheum* 58(12): 3684-3692. Osterloh, A., U. Kalinke, et al. (2007). "Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide." *J Biol Chem* 282(7): 4669-4680. Park, B. S., D. H. Song, et al. (2009). "The structural basis of lipopolysaccharide recognition


Joosten, L. A., M. I. Koenders, et al. (2003). "Toll-like receptor 2 pathway drives streptococcal

Kakimoto, K., A. Matsukawa, et al. (1995). "Suppressive effect of a neutrophil elastase

Kilding, R., M. Akil, et al. (2003). "A biologically important single nucleotide polymorphism

Kim, K. W., M. L. Cho, et al. (2007). "Human rheumatoid synovial fibroblasts promote

Kim, S., H. Takahashi, et al. (2009). "Carcinoma-produced factors activate myeloid cells

Krishnadas, R. and J. Cavanagh (2011). "Sustained remission of rheumatoid arthritis with a

Kubarenko, A. V., S. Ranjan, et al. (2010). "Comprehensive modeling and functional analysis of Toll-like receptor ligand-recognition domains." *Protein Sci* 19(3): 558-569. Kuhn, K. A., L. Kulik, et al. (2006). "Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis." *J Clin Invest* 116(4): 961-973. Lang, K. S., M. Recher, et al. (2005). "Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease." *Nat Med* 11(2): 138-145. Lartigue, A., P. Courville, et al. (2006). "Role of TLR9 in anti-nucleosome and anti-DNA

Leadbetter, E. A., I. R. Rifkin, et al. (2002). "Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors." *Nature* 416(6881): 603-607. Lee, E. K., S. M. Kang, et al. (2005). "Essential roles of Toll-like receptor-4 signaling in

Lefevre, S., A. Knedla, et al. (2009). "Synovial fibroblasts spread rheumatoid arthritis to

Lenert, P. S. (2010). "Classification, mechanisms of action, and therapeutic applications of

Leung, B. P., D. Xu, et al. (2004). "A novel therapy of murine collagen-induced arthritis with

Li, J., Y. Wan, et al. (2010). "Altered microRNA expression profile with miR-146a

Lindstrom, T. M. and W. H. Robinson (2010). "A multitude of kinases--which are the best targets in treating rheumatoid arthritis?" *Rheum Dis Clin North Am* 36(2): 367-383. Liu, L., I. Botos, et al. (2008). "Structural basis of toll-like receptor 3 signaling with double-

through TLR2 to stimulate metastasis." *Nature* 457(7225): 102-106.

88." *J Immunol* 171(11): 6145-6153.

*Exp Rheumatol* 21(3): 340-342.

*Immunol Lett* 110(1): 54-64.

literature." *J Med Case Reports* 5: 112.

unaffected joints." *Nat Med* 15(12): 1414-1420.

soluble T1/ST2." *J Immunol* 173(1): 145-150.

stranded RNA." *Science* 320(5874): 379-381.

32.

1349-1354.

2010: 986596.

*Ther* 12(3): R81.

cell wall-induced joint inflammation: critical role of myeloid differentiation factor

inhibitor on the development of collagen-induced arthritis." *Cell Immunol* 165(1): 26-

within the toll-like receptor-4 gene is not associated with rheumatoid arthritis." *Clin* 

osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation."

specific serotonin reuptake inhibitor antidepressant: a case report and review of the

antibody production in lpr mutation-induced murine lupus." *J Immunol* 177(2):

arthritis induced by type II collagen antibody and LPS." *Int Immunol* 17(3): 325-333.

inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9." *Mediators Inflamm*

upregulation in CD4+ T cells from patients with rheumatoid arthritis." *Arthritis Res* 


Targeting DAMP Activation of

*Rheum* 63(1): 53-62.

*Rheumatol* 5(10): 572-577.

*Rheum* 48(4): 876-881.

*Res Ther* 12(6): R219.

368(9538): 855-863.

*Commun* 372(4): 703-707.

518-530.

*Rev Rheumatol* 5(10): 531-541.

arthritis." *N Engl J Med* 312(13): 818-822.

63(2): 373-381.

1009.

462.

Toll-Like Receptors: Novel Pathways to Treat Rheumatoid Arthritis? 231

Sokolove, J., X. Zhao, et al. (2011). "Immune complexes containing citrullinated fibrinogen

Stanczyk, J., C. Ospelt, et al. (2011). "Altered expression of microRNA-203 in rheumatoid

Stanczyk, J., D. M. Pedrioli, et al. (2008). "Altered expression of MicroRNA in synovial

Tamaki, Y., Y. Takakubo, et al. (2011). "Expression of Toll-like Receptors and Their Signaling

Taylor, P. C. and M. Feldmann (2009). "Anti-TNF biologic agents: still the therapy of choice

Tedder, T. F. (2009). "CD19: a promising B cell target for rheumatoid arthritis." *Nat Rev* 

Townsend, M. J., J. G. Monroe, et al. (2010). "B-cell targeted therapies in human autoimmune

Uchida, Y., M. C. Freitas, et al. (2009). "The inhibition of neutrophil elastase ameliorates

Ulloa, L., F. M. Batliwalla, et al. (2003). "High mobility group box chromosomal protein 1 as

Uysal, H., R. Bockermann, et al. (2009). "Structure and pathogenicity of antibodies specific

van Beers, J. J., R. Raijmakers, et al. (2010). "Mapping of citrullinated fibrinogen B-cell

van Vollenhoven, R. F. (2009). "Treatment of rheumatoid arthritis: state of the art 2009." *Nat* 

Vanags, D., B. Williams, et al. (2006). "Therapeutic efficacy and safety of chaperonin 10 in

Wang, H., H. Liao, et al. (2004). "Cholinergic agonists inhibit HMGB1 release and improve

Wang, L., R. A. Gordon, et al. (2010). "Indirect inhibition of Toll-like receptor and type I

Weinblatt, M. E., J. S. Coblyn, et al. (1985). "Efficacy of low-dose methotrexate in rheumatoid

Wu, C. Y., P. L. Chi, et al. (2010). "TLR4-dependent induction of vascular adhesion molecule-

Yuan, Z., J. Chen, et al. (2008). "Construction and characterization of the HMGB1 mutant as

survival in experimental sepsis." *Nat Med* 10(11): 1216-1221.

A(2)alpha/cyclooxygenase-2." *J Cell Physiol* 223(2): 480-491.

mouse liver damage due to ischemia and reperfusion." *Liver Transpl* 15(8): 939-947.

a nuclear protein, cytokine, and potential therapeutic target in arthritis." *Arthritis* 

for citrullinated collagen type II in experimental arthritis." *J Exp Med* 206(2): 449-

epitopes in rheumatoid arthritis by imaging surface plasmon resonance." *Arthritis* 

patients with rheumatoid arthritis: a double-blind randomised trial." *Lancet*

interferon responses by ITAM-coupled receptors and integrins." *Immunity* 32(4):

1 in rheumatoid arthritis synovial fibroblasts: Roles of cytosolic phospholipase

a competitive antagonist to HMGB1 induced cytokines release." *Biochem Biophys Res* 

Pathways in Rheumatoid Synovitis." *J Rheumatol* 38(5): 810-820.

diseases: an updated perspective." *Immunol Rev* 237(1): 264-283.

for rheumatoid arthritis." *Nat Rev Rheumatol* 5(10): 578-582.

costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor." *Arthritis* 

arthritis synovial fibroblasts and its role in fibroblast activation." *Arthritis Rheum*

fibroblasts and synovial tissue in rheumatoid arthritis." *Arthritis Rheum* 58(4): 1001-


Roelofs, M. F., S. Abdollahi-Roodsaz, et al. (2008). "The orchestra of Toll-like receptors and

Roelofs, M. F., L. A. Joosten, et al. (2005). "The expression of toll-like receptors 3 and 7 in

Roelofs, M. F., M. H. Wenink, et al. (2009). "Type I interferons might form the link between

Rothlin, C. V., S. Ghosh, et al. (2007). "TAM receptors are pleiotropic inhibitors of the innate

Sacre, S., M. Medghalchi, et al. (2010). "Fluoxetine and citalopram exhibit potent

Sacre, S. M., E. Andreakos, et al. (2007). "The Toll-like receptor adaptor proteins MyD88 and

Sacre, S. M., S. K. Drexler, et al. (2007). "Could toll-like receptors provide a missing link in

Sacre, S. M., A. Lo, et al. (2008). "Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures." *J Immunol* 181(11): 8002-8009. Sanchez, E., G. Orozco, et al. (2004). "Polymorphisms of toll-like receptor 2 and 4 genes in

Scaffidi, P., T. Misteli, et al. (2002). "Release of chromatin protein HMGB1 by necrotic cells

Schmidt, M., B. Raghavan, et al. (2010). "Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel." *Nat Immunol* 11(9): 814-819. Schumacher, H. R., Jr., T. Arayssi, et al. (1999). "Chlamydia trachomatis nucleic acids can be

Seibl, R., T. Birchler, et al. (2003). "Expression and regulation of Toll-like receptor 2 in

Shi, Z., Z. Cai, et al. (2011). "A novel Toll-like receptor that recognizes vesicular stomatitis

Silva, E., J. Arcaroli, et al. (2007). "HMGB1 and LPS induce distinct patterns of gene

Scott, D. L., F. Wolfe, et al. (2010). "Rheumatoid arthritis." *Lancet* 376(9746): 1094-1108. Sebbag, M., N. Moinard, et al. (2006). "Epitopes of human fibrin recognized by the

rheumatoid arthritis synovium." *Am J Pathol* 162(4): 1221-1227.

rheumatoid arthritis (RA)." *Ann Rheum Dis* 68(9): 1486-1493.

and inhibit toll-like receptors." *Arthritis Rheum* 62(3): 683-693.

model of rheumatoid arthritis." *Am J Pathol* 170(2): 518-525.

rheumatoid tissue." *Ann Rheum Dis* 66 Suppl 3: iii81-86.

triggers inflammation." *Nature* 418(6894): 191-195.

immune response." *Cell* 131(6): 1124-1136.

58(2): 338-348.

57.

1284.

*Immunol* 36(8): 2250-2263.

virus." *J Biol Chem* 286(6): 4517-4524.

lung injury." *Intensive Care Med* 33(10): 1829-1839.

*Rheum* 52(8): 2313-2322.

their potential role in frequently occurring rheumatic conditions." *Arthritis Rheum*

rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells." *Arthritis* 

Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in

antiinflammatory activity in human and murine models of rheumatoid arthritis

Mal/TIRAP contribute to the inflammatory and destructive processes in a human

chronic inflammation in rheumatoid arthritis? Lessons from a study on human

rheumatoid arthritis and systemic lupus erythematosus." *Tissue Antigens* 63(1): 54-

found in the synovium of some asymptomatic subjects." *Arthritis Rheum* 42(6): 1281-

rheumatoid arthritis-specific autoantibodies to citrullinated proteins." *Eur J* 

expression and activation in neutrophils from patients with sepsis-induced acute


**12** 

*Slovakia* 

**Modern Pharmacological Approaches to Therapies: Substances Tested in Animal** 

*1Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences,* 

Preclinical research on animal models of rheumatoid arthritis (RA) is very important for alerting the healthcare and scientific community and pharmaceutical companies of the existence of new or "forgotten" molecules. Most antirheumatics have side-effects when used in higher doses and/or within long-term dosage. Combinatory therapy is expected to have a higher efficacy without increased toxicity. Methotrexate (MTX) has become the main immunosuppressive substance used in the treatment of patients with RA. However, the use of MTX has to be limited due to its toxic manifestations, e.g. abdominal disorder, alopecia, oral ulcers, and cytopenia (Alarcon et al., 1989). Ineffectiveness of treatment can be also observed. In the survey of McKendry and Dale (McKendry & Dale, 1993), due to the risk of treatment, termination was substantiated in 75% of patients with RA taking MTX for 60 months. An adverse drug effect proved to be a more common reason for treatment termination (53%) compared to loss/lack of beneficial effect (22%), other reasons (16%), or lost of follow-up (9%). On the other hand, the therapeutic efficacy of MTX can be increased by combination with other synthetic drugs or inhibitors of TNF-α (Smolen et al., 2010). Application of biological therapy (antibodies or soluble receptors of TNF-α, IL-1 and IL-6) represents a great progress in the therapy of RA. Yet biological treatment is also frequently combined with MTX (Maini et al., 1998; Weinblatt et al., 1999). There are countless possibilities for combinations with MTX. Many substances were neglected when they failed to show good efficacy in monotherapy compared to standard antirheumatics. They would not get a second chance if the expected reduction of clinical parameters (mainly edema of joints) did not materialize, despite the fact that they improved many biochemical disease markers. Our research in the last years was focused on evaluation of new therapeutics for the combinations of the classical immunosuppressive treatment with immunomodulators

Development of drugs for the therapy of RA has been very intensive in recent years. Biological therapy targeted on neutralizing the effect of antiinflammatory cytokines, particularly TNF-α, IL-1 and IL-6, by using antibodies or soluble receptors provided a great progress in RA therapy. However, not even these expensive drugs are able to cure RA

and compounds affecting reduction/oxidation homeostasis.

**1. Introduction** 

**Models of Rheumatoid Arthritis** 

Maria Stančikova2 and Jozef Rovensky2

*2National Institute of Rheumatic Diseases* 

Katarina Bauerova1, Silvester Poništ1, Radomir Nosaľ1,

